These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 30772387)

  • 1. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.
    Benza RL; Gomberg-Maitland M; Elliott CG; Farber HW; Foreman AJ; Frost AE; McGoon MD; Pasta DJ; Selej M; Burger CD; Frantz RP
    Chest; 2019 Aug; 156(2):323-337. PubMed ID: 30772387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison Between REVEAL Lite 2 and COMPERA 2.0 for Risk Stratification in Pulmonary Arterial Hypertension.
    Sahay S; Villasmil Hernandez N; Wang F; Wooten M; Nguyen DT; Fauvel C; Benza R; Graviss EA
    Chest; 2024 Aug; 166(2):373-387. PubMed ID: 38447640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the European Society of Cardiology/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator.
    Ahmed A; Ahmed S; Kempe D; Rådegran G
    Eur Heart J Open; 2023 Mar; 3(2):oead012. PubMed ID: 36959867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension.
    Benza RL; Kanwar MK; Raina A; Scott JV; Zhao CL; Selej M; Elliott CG; Farber HW
    Chest; 2021 Jan; 159(1):337-346. PubMed ID: 32882243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension.
    Benza RL; Gomberg-Maitland M; Miller DP; Frost A; Frantz RP; Foreman AJ; Badesch DB; McGoon MD
    Chest; 2012 Feb; 141(2):354-362. PubMed ID: 21680644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk assessment in patients with functional class II pulmonary arterial hypertension: Comparison of physician gestalt with ESC/ERS and the REVEAL 2.0 risk score.
    Sahay S; Tonelli AR; Selej M; Watson Z; Benza RL
    PLoS One; 2020; 15(11):e0241504. PubMed ID: 33175857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporation of renal function in mortality risk assessment for pulmonary arterial hypertension.
    Zelt JGE; Hossain A; Sun LY; Mehta S; Chandy G; Davies RA; Contreras-Dominguez V; Dunne R; Doyle-Cox C; Wells G; Stewart DJ; Mielniczuk LM
    J Heart Lung Transplant; 2020 Jul; 39(7):675-685. PubMed ID: 32336606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
    Mullin CJ; Khair RM; Damico RL; Kolb TM; Hummers LK; Hassoun PM; Steen VD; Mathai SC;
    Arthritis Rheumatol; 2019 Oct; 71(10):1691-1700. PubMed ID: 31066998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Risk Stratification Scores in Pulmonary Arterial Hypertension: A Monocentric Retrospective Study at Lausanne University Hospital.
    Vraka A; Yerly P; Aubert JD
    Respiration; 2022; 101(6):565-576. PubMed ID: 35045412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective Validation of the REVEAL 2.0 Risk Score With the Australian and New Zealand Pulmonary Hypertension Registry Cohort.
    Anderson JJ; Lau EM; Lavender M; Benza R; Celermajer DS; Collins N; Corrigan C; Dwyer N; Feenstra J; Horrigan M; Keating D; Kermeen F; Kotlyar E; McWilliams T; Rhodes B; Steele P; Thakkar V; Williams T; Whitford H; Whyte K; Weintraub R; Wrobel JP; Keogh A; Strange G
    Chest; 2020 Jan; 157(1):162-172. PubMed ID: 31563497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Contemporary Risk Scores in All Groups of Pulmonary Hypertension: A Pulmonary Vascular Research Institute GoDeep Meta-Registry Analysis.
    Yogeswaran A; Gall H; Fünderich M; Wilkins MR; Howard L; Kiely DG; Lawrie A; Hassoun PM; Sirenklo Y; Torbas O; Sweatt AJ; Zamanian RT; Williams PG; Frauendorf M; Arvanitaki A; Giannakoulas G; Saleh K; Sabbour H; Cajigas HR; Frantz R; Al Ghouleh I; Chan SY; Brittain E; Annis JS; Pepe A; Ghio S; Orfanos S; Anthi A; Majeed RW; Wilhelm J; Ghofrani HA; Richter MJ; Grimminger F; Sahay S; Tello K; Seeger W;
    Chest; 2024 Sep; 166(3):585-603. PubMed ID: 38508334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Derivation of a Risk Score (REVEAL-ECHO) Based on Echocardiographic Parameters of Patients With Pulmonary Arterial Hypertension.
    El-Kersh K; Zhao C; Elliott G; Farber HW; Gomberg-Maitland M; Selej M; Garcia-Ferrer J; Benza R
    Chest; 2023 May; 163(5):1232-1244. PubMed ID: 36634897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry.
    Boucly A; Weatherald J; Savale L; de Groote P; Cottin V; Prévot G; Chaouat A; Picard F; Horeau-Langlard D; Bourdin A; Jutant EM; Beurnier A; Jevnikar M; Jaïs X; Simonneau G; Montani D; Sitbon O; Humbert M
    Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34737227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Humbert M; Farber HW; Ghofrani HA; Benza RL; Busse D; Meier C; Hoeper MM
    Eur Respir J; 2019 Jun; 53(6):. PubMed ID: 30923187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of risk assessment tools in predicting hemodynamic outcome after balloon pulmonary angioplasty: a comparative analysis.
    Li X; Zhang Y; Zhao Q; Yang T; Zeng Q; Jin Q; Duan A; Huang Z; Hu M; Zhang S; Gao L; Xiong C; Luo Q; Zhao Z; Liu Z
    Postgrad Med; 2024 May; 136(4):446-455. PubMed ID: 38785198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk stratification in pulmonary arterial hypertension using Bayesian analysis.
    Kanwar MK; Gomberg-Maitland M; Hoeper M; Pausch C; Pittrow D; Strange G; Anderson JJ; Zhao C; Scott JV; Druzdzel MJ; Kraisangka J; Lohmueller L; Antaki J; Benza RL
    Eur Respir J; 2020 Aug; 56(2):. PubMed ID: 32366491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis.
    Benza RL; Miller DP; Foreman AJ; Frost AE; Badesch DB; Benton WW; McGoon MD
    J Heart Lung Transplant; 2015 Mar; 34(3):356-61. PubMed ID: 25447572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Risk of Disease Progression in Pulmonary Arterial Hypertension: Insights from an International Survey of Clinical Practice.
    Simons JE; Mann EB; Pierozynski A
    Adv Ther; 2019 Sep; 36(9):2351-2363. PubMed ID: 31313097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials.
    Scott JV; Garnett CE; Kanwar MK; Stockbridge NL; Benza RL
    Am J Respir Crit Care Med; 2021 Mar; 203(6):726-736. PubMed ID: 32937078
    [No Abstract]   [Full Text] [Related]  

  • 20. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
    Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF
    Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.